35449020|t|Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
35449020|a|BACKGROUND: Current hyponatraemia guidelines are divided on the use of tolvaptan in hospitalised patients with moderate to severe hyponatraemia, due to an uncertain risk-benefit ratio. We will conduct a randomised trial to test the hypothesis that early use of tolvaptan improves the rate of serum sodium correction and clinical outcomes compared with current standard first-line therapy, restriction of fluid intake, without increasing the risk of serum sodium overcorrection. METHODS: We will enrol hospitalised patients with euvolaemic or hypervolaemic hyponatraemia and serum sodium of 115-130 mmol/L at Austin Health, a tertiary care centre in Melbourne, Australia. Participants will be randomised 1:1 to receive either tolvaptan (initial dose 7.5 mg) or fluid restriction (initial limit 1000 ml per 24 h), with titration of therapy based on serum sodium response according to a pre-determined protocol over a 72-h intervention period. The primary endpoint will be the between-group change in serum sodium over time, from study day 1 to day 4. Secondary endpoints include serum sodium increment in the first 24 and 48 h, proportion of participants with normalised serum sodium, length of hospital stay, requirement for serum sodium re-lowering with intravenous dextrose or desmopressin, cognitive and functional measures (Confusion Assessment Method Short form, Timed Up and Go test, hyponatraemia symptom questionnaire), 30-day readmission rate, treatment satisfaction score and serum sodium 30 days after discharge. The trial will be overseen by an independent Data Safety Monitoring Board. Serum sodium will be monitored every 6-12 h throughout the study period, with pre-specified thresholds for commencing intravenous 5% dextrose if serum sodium rise targets are exceeded. DISCUSSION: We seek to inform future international guidelines with high-quality data regarding the utility and safety of tolvaptan compared to standard therapy fluid restriction in patients with moderate-severe hyponatraemia in hospital. If tolvaptan use in this patient group is endorsed by our findings, we will have established an evidence-based framework for tolvaptan initiation and monitoring to guide its use. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Registry ACTRN12619001683123 . Registered on December 2 2019.
35449020	0	9	Tolvaptan	Chemical	MESH:D000077602
35449020	59	67	patients	Species	9606
35449020	91	104	hyponatraemia	Disease	
35449020	111	117	HypoNa	Disease	
35449020	201	214	hyponatraemia	Disease	
35449020	252	261	tolvaptan	Chemical	MESH:D000077602
35449020	278	286	patients	Species	9606
35449020	311	324	hyponatraemia	Disease	
35449020	442	451	tolvaptan	Chemical	MESH:D000077602
35449020	479	485	sodium	Chemical	MESH:D012964
35449020	636	642	sodium	Chemical	MESH:D012964
35449020	695	703	patients	Species	9606
35449020	737	750	hyponatraemia	Disease	
35449020	761	767	sodium	Chemical	MESH:D012964
35449020	906	915	tolvaptan	Chemical	MESH:D000077602
35449020	1034	1040	sodium	Chemical	MESH:D012964
35449020	1185	1191	sodium	Chemical	MESH:D012964
35449020	1264	1270	sodium	Chemical	MESH:D012964
35449020	1356	1362	sodium	Chemical	MESH:D012964
35449020	1411	1417	sodium	Chemical	MESH:D012964
35449020	1447	1455	dextrose	Chemical	MESH:D005947
35449020	1570	1591	hyponatraemia symptom	Disease	MESH:D012816
35449020	1672	1678	sodium	Chemical	MESH:D012964
35449020	1785	1791	sodium	Chemical	MESH:D012964
35449020	1912	1920	dextrose	Chemical	MESH:D005947
35449020	1930	1936	sodium	Chemical	MESH:D012964
35449020	2085	2094	tolvaptan	Chemical	MESH:D000077602
35449020	2145	2153	patients	Species	9606
35449020	2175	2188	hyponatraemia	Disease	
35449020	2205	2214	tolvaptan	Chemical	MESH:D000077602
35449020	2227	2234	patient	Species	9606
35449020	2327	2336	tolvaptan	Chemical	MESH:D000077602
35449020	Association	MESH:D000077602	MESH:D012964
35449020	Negative_Correlation	MESH:D005947	MESH:D012964

